These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 19931385)

  • 1. Targeting the tumor microenvironment with anti-neu/anti-CD40 conjugated nanoparticles for the induction of antitumor immune responses.
    Dominguez AL; Lustgarten J
    Vaccine; 2010 Feb; 28(5):1383-90. PubMed ID: 19931385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic targeting of CpG-ODN to the tumor microenvironment with anti-neu-CpG hybrid molecule and T regulatory cell depletion induces memory responses in BALB-neuT tolerant mice.
    Sharma S; Dominguez AL; Manrique SZ; Cavallo F; Sakaguchi S; Lustgarten J
    Cancer Res; 2008 Sep; 68(18):7530-40. PubMed ID: 18794141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses.
    Rosalia RA; Cruz LJ; van Duikeren S; Tromp AT; Silva AL; Jiskoot W; de Gruijl T; Löwik C; Oostendorp J; van der Burg SH; Ossendorp F
    Biomaterials; 2015 Feb; 40():88-97. PubMed ID: 25465442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD40 ligation in vivo can induce T cell independent antitumor effects even against immunogenic tumors.
    Rakhmilevich AL; Buhtoiarov IN; Malkovsky M; Sondel PM
    Cancer Immunol Immunother; 2008 Aug; 57(8):1151-60. PubMed ID: 18214476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective Combination of Innate and Adaptive Immunotherapeutic Approaches in a Mouse Melanoma Model.
    Rakhmilevich AL; Felder M; Lever L; Slowinski J; Rasmussen K; Hoefges A; Van De Voort TJ; Loibner H; Korman AJ; Gillies SD; Sondel PM
    J Immunol; 2017 Feb; 198(4):1575-1584. PubMed ID: 28062694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimized DNA vaccines to specifically induce therapeutic CD8 T cell responses against autochthonous breast tumors.
    Cho HI; Niu G; Bradley N; Celis E
    Cancer Immunol Immunother; 2008 Nov; 57(11):1695-703. PubMed ID: 18253731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced HER-2/neu-specific antitumor immunity by cotransduction of mouse dendritic cells with two genes encoding HER-2/neu and alpha tumor necrosis factor.
    Chen Z; Huang H; Chang T; Carlsen S; Saxena A; Marr R; Xing Z; Xiang J
    Cancer Gene Ther; 2002 Sep; 9(9):778-86. PubMed ID: 12189528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication.
    van Mierlo GJ; Boonman ZF; Dumortier HM; den Boer AT; Fransen MF; Nouta J; van der Voort EI; Offringa R; Toes RE; Melief CJ
    J Immunol; 2004 Dec; 173(11):6753-9. PubMed ID: 15557168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A CD40 Agonist and PD-1 Antagonist Antibody Reprogram the Microenvironment of Nonimmunogenic Tumors to Allow T-cell-Mediated Anticancer Activity.
    Ma HS; Poudel B; Torres ER; Sidhom JW; Robinson TM; Christmas B; Scott B; Cruz K; Woolman S; Wall VZ; Armstrong T; Jaffee EM
    Cancer Immunol Res; 2019 Mar; 7(3):428-442. PubMed ID: 30642833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of CTL responses by simultaneous administration of liposomal peptide vaccine with anti-CD40 and anti-CTLA-4 mAb.
    Ito D; Ogasawara K; Iwabuchi K; Inuyama Y; Onoé K
    J Immunol; 2000 Feb; 164(3):1230-5. PubMed ID: 10640735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The CD8+ T cell repertoire against Her-2/neu antigens in neu transgenic mice is of low avidity with antitumor activity.
    Lustgarten J; Dominguez AL; Cuadros C
    Eur J Immunol; 2004 Mar; 34(3):752-761. PubMed ID: 14991605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD40-targeted recombinant adenovirus significantly enhances the efficacy of antitumor vaccines based on dendritic cells and B cells.
    Kim YS; Kim YJ; Lee JM; Han SH; Ko HJ; Park HJ; Pereboev A; Nguyen HH; Kang CY
    Hum Gene Ther; 2010 Dec; 21(12):1697-706. PubMed ID: 20604681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peptide vaccination breaks tolerance to HER-2/neu by generating vaccine-specific FasL(+) CD4(+) T cells: first evidence for intratumor apoptotic regulatory T cells.
    Gritzapis AD; Voutsas IF; Lekka E; Papamichail M; Baxevanis CN
    Cancer Res; 2010 Apr; 70(7):2686-96. PubMed ID: 20233867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-Her-2/neu-IL-2 or heregulin-IL-2 fusions proteins redirect non-tumor specific CTL to the tumor site for tumor eradication.
    Lustgarten J
    Cancer Immunol Immunother; 2003 Dec; 52(12):751-60. PubMed ID: 12827309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanoparticle Conjugation of Human Papillomavirus 16 E7-long Peptides Enhances Therapeutic Vaccine Efficacy against Solid Tumors in Mice.
    Galliverti G; Tichet M; Domingos-Pereira S; Hauert S; Nardelli-Haefliger D; Swartz MA; Hanahan D; Wullschleger S
    Cancer Immunol Res; 2018 Nov; 6(11):1301-1313. PubMed ID: 30131378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD40 and CD70 co-stimulate a potent in vivo antitumor T cell response.
    Nieland JD; Graus YF; Dortmans YE; Kremers BL; Kruisbeek AM
    J Immunother; 1998 May; 21(3):225-36. PubMed ID: 9610915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo expansion, persistence, and function of peptide vaccine-induced CD8 T cells occur independently of CD4 T cells.
    Assudani D; Cho HI; DeVito N; Bradley N; Celis E
    Cancer Res; 2008 Dec; 68(23):9892-9. PubMed ID: 19047170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delayed tumor onset and reduced tumor growth progression after immunization with a Her-2/neu multi-peptide vaccine and IL-12 in c-neu transgenic mice.
    Wagner S; Jasinska J; Breiteneder H; Kundi M; Pehamberger H; Scheiner O; Zielinski CC; Wiedermann U
    Breast Cancer Res Treat; 2007 Nov; 106(1):29-38. PubMed ID: 17203384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination with dendritic cells pulsed with apoptotic tumors in combination with anti-OX40 and anti-4-1BB monoclonal antibodies induces T cell-mediated protective immunity in Her-2/neu transgenic mice.
    Cuadros C; Dominguez AL; Lollini PL; Croft M; Mittler RS; Borgström P; Lustgarten J
    Int J Cancer; 2005 Oct; 116(6):934-43. PubMed ID: 15856473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poly (I:C)-DOTAP cationic nanoliposome containing multi-epitope HER2-derived peptide promotes vaccine-elicited anti-tumor immunity in a murine model.
    Alipour Talesh G; Ebrahimi Z; Badiee A; Mansourian M; Attar H; Arabi L; Jalali SA; Jaafari MR
    Immunol Lett; 2016 Aug; 176():57-64. PubMed ID: 27260485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.